Data/hora: 05/06/2024 09:06:29

Provedor de dados: | 56
País: | Brazil
Título: | Effect of a selective nonsteroidal anti-inflammatory inhibitor of cyclooxygenase-2 on the small bowel of rats
Autores: | Leite,A.Z.A.; Sipahi,A.M.; Damião,A.O.M.C.; Garcez,A.T.; Buchpiguel,C.A.; Lopasso,F.P.; Lordello,M.L.L.; Agostinho,C.L.O.; Laudanna,A.A.
Data: | 2004-03-01
Ano: | 2004
Palavras-chave: | Intestinal permeability; Enteropathy; Nonsteroidal anti-inflammatory drugs; Indomethacin; Rofecoxib; COX-2 inhibitor.
Resumo: | The pathogenesis of nonsteroidal anti-inflammatory drug (NSAID) enteropathy is a complex process involving the uncoupling of mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase (COX). Rofecoxib, a selective inhibitor of COX-2, has shown less gastric damage, but the same beneficial effect is not clear in the case of the small bowel. Fifty-seven male Wistar rats (250-350 g) were divided into three groups (N = 19 each) to evaluate the effect of this NSAID on the rat intestine. The groups received 2.5 mg/kg rofecoxib, 7.5 mg/kg indomethacin or water with 5% DMSO (control) given as a single dose by gavage 24 h before the beginning of the experiment. A macroscopic score was used to quantify intestinal lesions and intestinal permeability was measured using [51Cr]-ethylenediaminetetraacetic acid ([51Cr]-EDTA). The extent of intestinal lesion, indicated by a macroscopic score, was significantly lower when rofecoxib was administered compared to indomethacin (rofecoxib = 0.0 vs indomethacin = 63.6 ± 25.9; P &lt; 0.05) and did not differ from control. The intestinal permeability to [51Cr]-EDTA was significantly increased after indomethacin (control = 1.82 ± 0.4 vs indomethacin = 9.12 ± 0.8%; P &lt; 0.0001), but not after rofecoxib, whose effect did not differ significantly from control (control = 1.82 ± 0.4 vs rofecoxib = 2.17 ± 0.4%; ns), but was significantly different from indomethacin (indomethacin = 9.12 ± 0.8 vs rofecoxib = 2.17 ± 0.4%; P &lt; 0.001). In conclusion, the present data show that rofecoxib is safer than indomethacin in rats because it does not induce macroscopic intestinal damage or increased intestinal permeability.
Tipo: | Info:eu-repo/semantics/other
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000300007
Editor: | Associação Brasileira de Divulgação Científica
Relação: | 10.1590/S0100-879X2004000300007
Formato: | text/html
Fonte: | Brazilian Journal of Medical and Biological Research  v.37 n.3 2004
Fonte: | info:eu-repo/semantics/openAccess